Impact of Intrathecal Therapy on Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Compared to a Historical Cohort: A Single Center Analysis

Key Points

• Neurotoxicity syndrome rates are significantly lower with intrathecal therapy, indicating improved patient safety.
• For patients receiving intrathecal therapy, the incidence of immune effector cell-associated neurotoxicity syndrome is reduced compared to historical data.
• This analysis compares outcomes using historical cohort data to assess changes in neurotoxicity risk.
• The findings underline the importance of intrathecal therapy in managing immune-related side effects effectively.